GlassScriptPhysician profile
Alex Steven Kalsbeck
NPI 1003451881
$1,437.79
in general payments reported to CMS, 2019-2025
24 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $602 · 2023: $356 · 2024: $226 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $212.42 | 2022-2025 | |
| Grifols USA, LLC | $209.22 | 2022-2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $171.90 | 2022-2025 | |
| Novo Nordisk INC | $109.68 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $101.35 | 2022-2025 | Evenity, Otezla, Repatha |
| Mylan Specialty L.P. | $81.06 | 2022-2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.13 | 2025 | Caplyta |
| Organon LLC | $54.20 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.37 | 2022-2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $50.81 | 2022-2024 | Xarelto |
| Vanda Pharmaceuticals INC. | $38.79 | 2022-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.98 | 2022-2023 | Jardiance |
| Lilly USA, LLC | $34.00 | 2024-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $29.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.56 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $21.52 | 2024 | Opsumit, Uptravi |
| Medtronic, INC. | $21.27 | 2025 | Minimed 780g |
| Baxter Healthcare | $19.86 | 2024 | |
| Abbvie INC. | $16.60 | 2022 | |
| Exact Sciences Corporation | $15.68 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $14.90 | 2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $14.74 | 2025 | Glassia |
| Sanofi Pasteur INC. | $14.18 | 2023 | |
| Merck Sharp & Dohme LLC | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Kalsbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.